

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2014/145199 A8

(43) International Publication Date
18 September 2014 (18.09.2014)

- (51) International Patent Classification:
A61K 31/711 (2006.01) *C12N 15/85* (2006.01)
A61P 9/00 (2006.01)
- (21) International Application Number:
PCT/US2014/029921
- (22) International Filing Date:
15 March 2014 (15.03.2014)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/792,954 15 March 2013 (15.03.2013) US
- (71) Applicants: **THE CLEVELAND CLINIC FOUNDATION** [US/US]; 9500 Euclid Avenue, Cleveland, OH 44195 (US). **JUVENTAS THERAPEUTICS, INC.** [US/US]; 3615 Superior Avenue, Suite 4403C, Cleveland, OH 44114 (US).
- (72) Inventor; and
(71) Applicant : **FISHER, Scott, J.**; 32571 Trailwood Court, Solon, OH 44139 (US).
- (72) Inventors: **PENN, Marc, S.**; 26091 Shaker Boulevard, Beachwood, OH 44122 (US). **ARAS, Rahul**; 150 Hartford Court, Broadview Heights, OH 44147 (US). **PASTORE, Joseph**; 7004 Easton Way W, Mentor, OH 44060 (US). **MILLER, Timothy, J.**; 2240 Delaware Drive, Cleveland Heights, OH 44106 (US).
- (74) Agents: **VALLA, S. Maurice** et al.; Baker & Hostetler LLP, 2929 Arch Street, Cira Centre, 12th Floor, Philadelphia, PA 19104-2891 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

[Continued on next page]

(54) Title: RETROGRADE DELIVERY OF SDF-1 FOR TREATMENT OF MYOCARDIAL INFARCTION

(57) Abstract: Described herein are methods of treating a subject with a cardiomyopathy by administering to the subject's heart, via percutaneous retrograde coronary sinus perfusion, a pharmaceutical composition that comprises a DNA plasmid encoding SDF-1 and a pharmaceutically acceptable carrier or diluent.



Figure 4

WO 2014/145199 A8



OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

- (88) **Date of publication of the international search report:**
6 November 2014

- (48) **Date of publication of this corrected version:**
4 December 2014

- (15) **Information about Correction:**
see Notice of 4 December 2014